The purpose of this study is to evaluate the impact of an extended oral Tranexamic Acid regimen on patient reported outcome scores, time to independent ambulation, postoperative range of motion, swelling, change in hemoglobin levels, 90-day complications, readmission and reoperation.

Start Date01 Dec 2025

Sponsor / Collaborator

Mayo Clinic

NCT07115056

/ Not yet recruitingPhase 4IIT

Extended Post-Operative Oral Tranexamic Acid Dosing After ACL Reconstruction: A Multicenter Randomized Controlled Trial

This is a prospective, multi-center, randomized, double-blind, placebo-controlled trial evaluating the efficacy of oral tranexamic acid (TXA) in improving postoperative outcomes following anterior cruciate ligament reconstruction (ACLR) using patellar tendon autograft in adolescent and young adult patients.
A total of 100 patients, aged 14 to 22 years and undergoing eligible ACLR, will be enrolled across multiple participating sites. Eligible participants will be randomized 1:1 to receive either oral TXA (1.95 g per day, divided into three 650 mg capsules) or placebo (microcrystalline cellulose) once daily from postoperative day 1 to 10, in addition to standard intraoperative care. All participants will receive 1 g IV TXA prior to incision and 1 g IV TXA at closure, per standard surgical protocol.
The primary outcome is improvement in postoperative pain, as measured by the Visual Analog Scale (VAS). Secondary outcomes are knee range of motion, quadriceps strength, isokinetic strength, time to straight leg raise, time to return to sport, International Knee Documentation Committee score, Lyshom score, and morphine milligram equivalents. Participants will be followed through routine postoperative visits at the participating institutions out to one year with a phone call for patient reported outcomes at 2 years.

Start Date01 Nov 2025

Sponsor / Collaborator

Campbell Clinic PC

[+4]

100 Clinical Results associated with Tranexamic Acid

100 Translational Medicine associated with Tranexamic Acid

100 Patents (Medical) associated with Tranexamic Acid

8,665

Literatures (Medical) associated with Tranexamic Acid

01 Feb 2026·JOURNAL OF CRITICAL CARE

Impact of different preferred functional outcomes on the results of the pre-hospital antifibrinolytics for traumatic coagulopathy and hemorrhage (PATCH-trauma) trial

Article

Author: Gartner, Dashiell C ; McArthur, Colin J ; Young, Paul J ; Forbes, Andrew B ; Burns, Brian ; Mitra, Biswadev ; Maegele, Marc ; Bernard, Stephen A ; Gruen, Russel L ; Zampieri, Fernando G

RATIONALE:

Ordinal endpoints offer more detailed outcome assessment than mortality, though some disabilities may be considered worse than death by patients.

OBJECTIVES:

To evaluate how different Glasgow Outcome Scale - Extended (GOS-E) hierarchical structures affect effect estimation in the PATCH-Trauma trial.

METHODS:

This post-hoc analysis of the PATCH-Trauma trial compared pre-hospital tranexamic acid (TXA) to placebo in severely injured patients at risk of acute traumatic coagulopathy. The study included patients with complete 6-month outcomes. Using generalized pairwise comparisons, researchers analyzed the 8-point GOS-E, ICU length-of-stay, and thromboembolic complications. Results were reported using win ratio (WR) statistics, with values above one favoring TXA. The analysis explored GOS-E with mortality rankings adjusted based on different outcomes being considered worse than death.

MAIN RESULTS:

The study included 1107 patients (546 placebo, 561 TXA). Original GOS-E results showed a neutral WR (1.03; 95 % CI 0.90-1.19). When death was considered preferable to progressively less impaired functionality (from vegetative state to upper moderate disability), the WR decreased to 0.86 (95 % CI 0.75-1.00).

CONCLUSION:

The assessment of TXA therapy's efficacy and safety may vary depending on scenarios where certain functional outcomes are considered worse than death. This analytical approach could inform functional outcome assessment in future acute care trials.

31 Dec 2025·Journal of Maternal-Fetal & Neonatal Medicine

Accordance between weight-based and calculated blood loss for obstetric hemorrhage: a pre-study to a randomized controlled trial

Article

Author: Skogvard, Linnea ; Endler, Margit ; Strindfors, Gita

OBJECTIVE:

Postpartum hemorrhage (PPH) is the leading cause of maternal death. Identifying excessive bleeding is crucial, but there is no gold standard for its measurement. We aimed to assess accordance between two formulas for calculated blood loss (CBL) and weight-based blood loss (WBBL) to determine if CBL has a place in either the clinical or research obstetric context.

METHOD:

This was a pre-posttest study nested in a pilot study. Women ≥ 18years and ≥ 36 gestational weeks with uncomplicated pregnancies and planned vaginal birth were included at a tertiary hospital in Stockholm, Sweden from December 2022 to February 2023. Hematocrit (Erythrocyte Volume Fraction, EVF) and hemoglobin (Hb) were taken at admission and 24 h postpartum. Blood loss was calculated in three ways: weighing blood collected in drapes and blood-soaked material; Gross's formula based on pre-postpartum EVF; and pre-postpartum Hb difference, assuming a 10 mg/L difference equivalent to 500 ml. We compared median blood loss between these methods using Related-samples Wilcoxon Signed-Rank Test, correlations using Spearman's Rho, and prediction of PPH (≥500 ml) using McNemar's test.

RESULTS:

Out of 51 women included in the pilot, 37 and 36 had data for each CBL method respectively. Median blood loss was 350 ml for WBBL, 649 ml for Gross's formula (p = 0.008) and 750 ml for pre-postpartum Hb difference (p < 0.001). For the diagnosis PPH, WBBL and Gross's formula were concordant in 61% of cases (p = 0.002), compared to 43% for WBBL and pre-postpartum Hb difference (p = 0.001). There was a moderate positive correlation between WBBL and both CBL methods (p = 0.001). Excluding women who received intravenous fluids did not improve agreement between WBBL and CBL methods.

DISCUSSION:

Both CBL methods significantly differ from, and overestimate bleeding compared to WBBL. There is a correlation between WBBL and CBL, but the estimates differ to the extent that CBL methods do not seem relevant for clinical obstetric practice or research.

01 Dec 2025·LUNG

Effectiveness of Inhalational Tranexamic Acid in Patients with Nonmassive Hemoptysis–A Systematic Review and Meta-Analysis

Review

Author: Krishnamoorthy, Yuvaraj ; Salih, Anas ; Elanjeran, Rajkumar ; Rajendran, Gunaseelan ; Dinesh, Vasudha ; Ramkumar, Anitha ; Kannan, Rahini ; Mahalingam, Sasikumar ; Thirthar Palanivelu, Elamurugan ; Ponnaeasu, Sathya Prakasham

BACKGROUND:

Hemoptysis, the expectoration of blood from the lower respiratory tract, varies in severity and necessitates effective management to mitigate morbidity. Traditional treatments include bronchial artery embolization and pharmacological approaches. Tranexamic acid (TXA), an antifibrinolytic agent known for its efficacy in reducing bleeding during surgery and trauma, is being explored for its efficacy in treating Hemoptysis via both intravenous and inhalational routes. Inhalational administration has garnered interest because of its targeted action and minimal systemic effects. This study aimed to assess the effectiveness of inhalational TXA in nonmassive hemoptysis.

METHODS:

A systematic literature search encompassing PubMed Central, EMBASE, SCOPUS, and ProQuest was conducted. Randomized controlled trials (RCTs) and observational studies assessing the effectiveness of inhalational tranexamic acid for nonmassive hemoptysis were included. Comparative intervention effect estimates from meta-analyses are reported as pooled odds ratios and pooled mean differences with 95% confidence interval (CI).

FINDINGS:

Analysis of three RCTs and two observational studies, comprising 351 patients (192 cases and 159 controls), revealed varying risk levels of bias across the studies. Nebulized tranexamic acid was 3.85 times more likely to achieve hemoptysis cessation than alternative treatments across all RCTs. Moreover, patients receiving nebulized tranexamic acid required fewer (43%) pulmonary interventional procedures than those receiving other treatments. Despite showing a trend towards reducing posttherapy bleeding (20 ml less), conclusive results were hindered by wide CI, necessitating further investigation.

INTERPRETATION:

Nebulized tranexamic acid may be a potential therapeutic option for nonmassive hemoptysis. While our analysis suggests its potential benefits in halting bleeding and reducing the need for invasive procedures, the quality of the available evidence is limited due to the risk of bias and study limitations. This underscores the necessity for additional randomized controlled trials with larger sample sizes and rigorous study designs to strengthen evidence and optimize clinical utility.

PROSPERO REGISTRATION:

The registration for this systematic review and meta-analysis was completed through Prospero on January 30, 2024, with the registration number CRD42024501624.

108

News (Medical) associated with Tranexamic Acid

09 Sep 2025

·www.einpresswire.com

A.forall expands US generics portfolio

Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach By integrating this portfolio with our existing capabilities, we focus to reach further into markets where high-quality generic medicines make the greatest difference,” — Steen Vangsgaard ANDERLECHT, BRUSSELS, BELGIUM, September 9, 2025 / EINPresswire.com / -- A.forall is pleased to announce the acquisition of four FDA-approved injectable generics and two late-stage pipeline assets from Provepharm's US portfolio. With this acquisition, A.forall considerably extends its marketed portfolio in the US, marking a significant expansion of its US footprint and a key milestone in the company’s sharpened focus on high-quality generics worldwide. Strengthening Essential Healthcare The acquired portfolio includes four well-established hospital products that address critical therapeutic needs: • Dihydroergotamine Mesylate (neurology – for the treatment of migraine and cluster headaches) • Piperacillin/Tazobactam (infectious disease – broad-spectrum antibiotic for hospital-acquired infections) • Tranexamic Acid (hematology – to control bleeding in surgical and trauma settings) • Phenylephrine Hydrochloride (anesthesiology – to manage hypotension during surgery) These medicines are widely integrated in US hospital protocols and marketed via established pharmaceutical distributors and group purchasing organizations, ensuring strong clinical familiarity among healthcare professionals. The newly acquired products will be commercialized through A.forall’s US subsidiary, Milla Pharmaceuticals Inc . The two late-stage pipeline products target complementary therapeutic areas and are expected to launch in the coming years. Steen Vangsgaard, CEO of A.forall, comments: “This acquisition fits perfectly with our renewed strategy to develop, commercialize and add value to medicines, increasing their availability where they matter most. These products expand our US relevance and give us immediate access to a robust portfolio that meets essential therapeutic needs. It’s a strategic investment that delivers scale, diversification and valuable cross-selling opportunities.” Strategic US Focus For A.forall, the US is a strategic priority. With a dedicated team on the ground, strong partnerships and a robust pipeline, the company continues to invest in one of the world’s most competitive and complex healthcare environments. Since 2017, six products of A.forall were registered successfully in the US market, demonstrating consistent growth and commitment to American healthcare providers. "By integrating this portfolio with our existing capabilities, we focus to reach further into markets where high-quality generic medicines make the greatest difference," Vangsgaard adds. "This acquisition strengthens our brand recognition and significantly expands our commercial presence in the world's largest pharmaceutical market." This acquisition follows the recent decision to divest A.forall's Retail & Hospital division and focus entirely on generics: a strategy that gives the company a sharper scope, stronger momentum and a clear direction for growth. About A.forall A.forall is a Belgian pharmaceutical group with headquarters in Anderlecht and offices in Ireland and the United States. At current, the company employs over 144 people and distributes a wide range of pharmaceutical products to pharmacies, wholesalers, hospitals and retirement homes. A.forall is also a global player in the generics market, now with 35+ molecules on the European and U.S. market and a fully stocked pipeline of mainly injectable generics and value-added products covering various therapeutic areas. Driven by one mission #MakingAffordableMedicinesAvailableToAll, A.forall focuses 100% on the development, licensing and commercialization of generic medicines worldwide. A.forall is part of The Riverside Company's portfolio, a global investment firm focused on the smaller end of the middle market that has invested in more than 220 healthcare companies since 1988. For more information, visit: www.aforallpharma.com . We’re happy to provide additional context or answer any questions you may have. For media inquiries or more information, please contact: A.forall Group NV Communication Department A.forall +32 2 526 64 14 communications@aforallpharma.com Visit us on social media: LinkedIn Steen Vangsgaard on the US expansion Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Acquisition

10 Jul 2025

·www.einpresswire.com

Antifibrinolytic Drugs Market to Hit $19.3 Billion by 2026 Amid Rising Demand for Hemorrhage Control

North America accounted for majority of the market share in 2018 and is anticipated to continue this trend during the forecast period. PORTLAND, OR, UNITED STATES, July 10, 2025 / EINPresswire.com / -- The Antifibrinolytic Drugs Market size was estimated at $13.59 billion in 2018 and is expected to hit at $19.33 billion by 2026, registering a CAGR of 4.5% from 2019 to 2026. The report provides a detailed analysis of the market size & estimations, top investment pockets, top winning strategies, drivers & opportunities, competitive scenario, and wavering market trends. ► Don't Miss Out “Download Your Exclusive Sample PDF Report” Now: https://www.alliedmarketresearch.com/request-sample/6279 Antifibrinolytics are one of the most commonly used drugs to prevent fibrinolysis by blocking the activation of plasminogen proenzyme and plasmin. This intervention is critical to avoid clotting in areas that are prone to fibrinolysis such as the oral cavity, nasal cavity and female genitalia. Recommended antifibrinolytic drugs include Epsilon aminocaproic acid, tranexamic acid, Amicar, aminocaproic acid, aprotinin, and Cyklokapron. Also, these drugs find their application in surgery such as heart surgery, neurosurgeries and dental surgery. In addition, women use antifibrinolytic drugs to control heavy menstruation. Major market players covered in the report, such as - Akorn Inc., Aurobindo Pharma Limited, Bayer AG, Ferring Holding SA, Mylan N.V., Novartis International AG (Sandoz), Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vitruvias Therapeutics Inc. Key Benefits for Stakeholders - • The report provides quantitative analysis of market segments, current trends, strategies and potential of antifibrinolytic drugs market research to identify potential antifibrinolytic drugs market opportunities in genetics. • In-depth analysis of this sector helps identify current market opportunities. • Market analysis and information related to key drivers, restraints and opportunities are provided. • Porter's Five Forces Analysis identifies the capabilities of buyers and suppliers to enable stakeholders to make profitable business decisions and strengthen the network of buyers. • The largest countries in each region are listed according to their contribution to the global market. • Focusing on market players makes benchmarking easier and provides a clear understanding of the current market situation. • The report includes regional and global antifibrinolytic drugs market analysis, key players, market segments, application areas and Market growth strategies. ★ Procure Complete Report [ 220 Pages PDF with Insights, Charts, Tables, and Figures ] @ https://www.alliedmarketresearch.com/request-for-customization/6279 Antifibrinolytic drugs or agents are used in specific situations or in combination with clotting factor replacement to treat hemophilia. These prevent the breakdown of blood clots by counteracting chemicals in the mucous membrane. Antifibrinolytics are increasingly being used in operations associated with high risk of bleeding. These drugs are useful in the management of optimal coagulation. TABLE OF CONTENT - CHAPTER 1 - INTRODUCTION: 1.1. Report description 1.2. Key market segments 1.3. List of key players profiled in the report 1.4. Research methodology 1.4.1. Secondary research 1.4.2. Primary research 1.4.3. Analyst tools & models CHAPTER 2 - EXECUTIVE SUMMARY: 2.1. Key findings of the study 2.2. CXO Perspective CHAPTER 3 - MARKET OVERVIEW: 3.1. Market Definition and Scope 3.2. Key Findings 3.2.1. Top investment pockets 3.2.2. Top winning strategies 3.3. Market Share Analysis/Top Player Positioning 3.4. Porter’s Five Forces Analysis 3.5. Market Dynamics 3.5.1. Drivers 3.5.2. Restraints 3.5.3. Opportunities… 3.6. COVID-19 Impact Analysis on the market North America accounted for the largest share of the antifibrinolytic drugs market in 2018 and is expected to continue this trend during the forecast period. This is due to the increasing number of women using these drugs to control heavy periods. Additionally, a significant increase in surgeries in this region is driving the market growth. However, the Asia-Pacific region is expected to experience rapid growth due to the rise in road accidents and the increase in the use of these drugs by women to control menstrual cycle. 👉 For Purchase Inquiry of Report: https://www.alliedmarketresearch.com/purchase-enquiry/6279 The antifibrinolytic drugs market is expected to witness a significant growth in the coming years. This market has gained interest of the healthcare and medical sectors owing to increased prevalence of hypertension throughout the globe. Furthermore, the global antifibrinolytic drugs market is segmented on the basis of product type, end user, and region. leading market players have been introducing various strategies to help enterprises move their on-premise models to on-demand models. Frequently Asked Questions? Q1. What is the total market value of antifibrinolytic drugs market report? Q2. Which are the top companies holding the market share in antifibrinolytic drugs market? Q3. Which are the largest regions for this Market? Q4. What is the leading technology of antifibrinolytic drugs market? Q5. What are the major drivers for this specific Market? Q6. What are the upcoming key trends in the antifibrinolytic drugs market report? About Us - Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. Pawan Kumar, the CEO of Allied Market Research is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various research data tables and confirms utmost accuracy in our market forecasting. Each and every us companies and this helps us in digging out market data that helps us generate accurate y data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry. David Correa Allied Market Research + +1 800-792-5285 email us here Visit us on social media: LinkedIn Facebook YouTube X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

19 Mar 2025

·www.pharmaindustrial-india.com

Nexus Pharmaceuticals Launches Tranexamic Acid

Nexus Pharmaceuticals, a US-based healthcare company, has introduced Tranexamic Acid. This milestone is another step for Nexus in its mission to provide life-saving medication to those who need it most. “We are very excited to be adding Tranexamic Acid to our product portfolio. Antifibrinolytic Agents, such as Tranexamic Acid, are crucial to have available in operating rooms and we are proud to contribute to the supply,” said Vince LoPiccolo, Vice President of Sales at Nexus. Tranexamic Acid is now available in cartons of 10 bags. Nexus Pharmaceuticals, LLC., a US-based healthcare company, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor intensive, and more streamlined in practice. Nexus ensures that its high-quality drug products fulfill a critical unmet medical need and deliver dependable life-saving treatment options when and where they’re needed most.

100 Deals associated with Tranexamic Acid

External Link

KEGG	Wiki	ATC	Drug Bank
D01136	Tranexamic Acid	B02AA02	DB00302

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Menorrhagia	United States	Amring Pharmaceuticals SA	13 Nov 2009
Hemophilia	United States	Pfizer Inc.	30 Dec 1986
Hemophilia	United States	Pharmacia & Upjohn, Inc.	30 Dec 1986
Erythema	Japan	Nipro Pharma Corp.	16 Jan 1969
Pruritus	Japan	Nipro Pharma Corp.	16 Jan 1969
Tumescence	Japan	Nipro Pharma Corp.	16 Jan 1969
Drug Eruptions	Japan	Daiichi Sankyo Co., Ltd.	31 Aug 1965
Hemorrhage	Japan	Daiichi Sankyo Co., Ltd.	31 Aug 1965
Pharyngolaryngitis	Japan	Daiichi Sankyo Co., Ltd.	31 Aug 1965
Stomatitis	Japan	Daiichi Sankyo Co., Ltd.	31 Aug 1965
Tonsillitis	Japan	Daiichi Sankyo Co., Ltd.	31 Aug 1965
Urticaria	Japan	Daiichi Sankyo Co., Ltd.	31 Aug 1965

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Intestinal Diseases	Phase 3	China	Hengyi Biopharmaceutical (Shanghai) Co., Ltd.	27 Mar 2023
Ileus	Phase 3	United States	Palisade Bio, Inc.	28 Jun 2022
Gastrointestinal dysfunction	Phase 3	China	Hengyi Biopharmaceutical (Shanghai) Co., Ltd.	30 Jan 2022
Cerebral Hemorrhage	Phase 3	Nepal	-	08 Feb 2021
Hematoma	Phase 3	Nepal	-	08 Feb 2021
Spinal fusion	Phase 3	United States	Exela Pharma Sciences LLC	17 Oct 2018
Colonic Cancer	Phase 3	Nepal	Pfizer Inc.	01 Jul 2012
Hepatocellular Carcinoma	Phase 3	Nepal	Pfizer Inc.	01 Jul 2012
Pancreatic Cancer	Phase 3	Nepal	Pfizer Inc.	01 Jul 2012
Stomach Cancer	Phase 3	Nepal	Pfizer Inc.	01 Jul 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04272606 (Pubmed \| BJA Open)	Phase 2	Delirium cytokines \| S100B	-	Tranexamic acid (TXA)	bnzovqjfqs(rumwsnmyqz) = usjszdskqk itudaiejim (cjrzgtuqzp ) View more	Positive	01 Jun 2025
				Placebo	bnzovqjfqs(rumwsnmyqz) = abrqhfzdwu itudaiejim (cjrzgtuqzp ) View more
NCT03505723 (POISE-3, Pubmed \| JAMA Surg)	Phase 3	-	9,535	Tranexamic Acid	esvgmczjnx(kkladsivnu): HR = 0.74 (95% CI, 0.59 - 0.93) View more	Positive	01 Mar 2025
				Placebo
NCT04344860 (VWD Woman Trial, ASH2024)	Phase 3	Von Willebrand Diseases \| Postpartum Hemorrhage	20	rVWF+TA	inpehqexzc(vnwvzpsvfq) = dknztgsigg hkboeaytnz (vkpqghihln ) View more	Negative	08 Dec 2024
				rVWF alone	inpehqexzc(vnwvzpsvfq) = rzvfunbrlz hkboeaytnz (vkpqghihln ) View more
NCT04410042 (CTgov)	Phase 3	Bone Cancer	15	Tranexamic Acid (Arm A-Tranexamic Acid)	bruvtowtad(iyphdzcqrs) = jjnvohokph scehuzozzb (ixuskzsnnc, 2.34) View more	-	05 Dec 2024
				Placebo (Arm B-Placebo)	bruvtowtad(iyphdzcqrs) = fimwscohzm scehuzozzb (ixuskzsnnc, 2.85) View more
NCT04541303 (CTgov)	Early Phase 1	Postoperative Hemorrhage \| Wounds and Injuries	124	tranexamic acid (Intervention)	ccnqivbhou = xigqbcrqdm aapsyvopqp (rnbxtbyuma, zbdnyhuwvz - lixpyhcpsf) View more	-	21 Nov 2024
				normal saline (Placebo)	ccnqivbhou = iuaiinoiyt aapsyvopqp (rnbxtbyuma, tedkgsqtpc - zlvdocdsxc) View more
NCT03954314 (DEPOSITION, Pubmed \| Circulation)	Phase 3	-	3,242	Topical Tranexamic Acid	hxwywwkacu(vhsbrbosiq) = zwbuljxlrm acwzukbrzq (osksvlxhod ) View more	Negative	22 Oct 2024
				Intravenous Tranexamic Acid	hxwywwkacu(vhsbrbosiq) = cmrdttwhoe acwzukbrzq (osksvlxhod ) View more
NCT02656472 (TXAEACA, CTgov)	Phase 4	Complication of extracorporeal circulation	22	tranexamic acid (Tranexamic Acid Arm)	mxgewqcvtv(rjhmlqvoza) = tgcdmfmzno wlzxiupywv (ffpwikcvsc, ihcxedcymb - mzjphllaoj) View more	-	22 Oct 2024
				Epsilon Aminocaproic Acid (Epsilon Aminocaproic Acid Arm)	mxgewqcvtv(rjhmlqvoza) = ulnjzyrvot wlzxiupywv (ffpwikcvsc, lwphfmcupn - rtwfgridlx) View more
NCT03923959 (TAHFT, CTgov)	Phase 3	Hip Fractures	283	Tranexamic Acid Injectable Solution (Intervention)	gpbkahodch = vmuseioqrk omqocscchh (cagiokvvui, eibeqlzzmf - zaybzbfovy) View more	-	10 Oct 2024
				Placebo (Placebo)	gpbkahodch = ezpldribeh omqocscchh (cagiokvvui, norafdovgi - eupkyugavx) View more
NCT01990768 (Prehospital Tranexamic Acid for TBI Trial, Pubmed \| J Trauma Acute Care Surg)	Phase 2	Intracranial Hemorrhage, Traumatic	966	2-g out-of-hospital TXA bolus	jtrgztjebh(irqvqhnwiv) = vgobjeveqy gtijlypint (hxlaimxlec )	Positive	01 Oct 2024
				1-g out-of-hospital TXA bolus/1-g in-hospital TXA infusion	jtrgztjebh(irqvqhnwiv) = czkfyjpxpj gtijlypint (hxlaimxlec )
NCT02546648 \| NCT03505723 (POISE-3, ESC2024)	Phase 3	-	9,535	Tranexamic acid (TXA)	chebdhjkzj(onxtswmvfy) = jnfvrvitve ohavkqagon (jutfvilvne, 0.88 - 1.42) View more	Negative	01 Sep 2024
				Placebo	chebdhjkzj(onxtswmvfy) = hagxstwquu ohavkqagon (jutfvilvne ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis